Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Capital Leases (2016 - 2018)

Kiora Pharmaceuticals' Capital Leases history spans 3 years, with the latest figure at $140.0 for Q3 2018.

  • For Q3 2018, Capital Leases fell 97.87% year-over-year to $140.0; the TTM value through Sep 2018 reached $140.0, down 97.87%, while the annual FY2017 figure was $4855.0, 69.79% down from the prior year.
  • Capital Leases reached $140.0 in Q3 2018 per KPRX's latest filing, down from $1712.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $16069.0 in Q4 2016 to a low of $140.0 in Q3 2018.
  • Average Capital Leases over 3 years is $6912.1, with a median of $5720.0 recorded in 2017.
  • Peak YoY movement for Capital Leases: crashed 69.79% in 2017, then tumbled 97.87% in 2018.
  • A 3-year view of Capital Leases shows it stood at $16069.0 in 2016, then plummeted by 69.79% to $4855.0 in 2017, then plummeted by 97.12% to $140.0 in 2018.
  • Per Business Quant, the three most recent readings for KPRX's Capital Leases are $140.0 (Q3 2018), $1712.0 (Q2 2018), and $3283.0 (Q1 2018).